Investigating a new aerosol treatment for asthma using a specific antagonist.
Pharmacokinetic and Efficacy Studies of the Aerosolized PAR2 Antagonist, C781, for the Treatment of Asthma
This study is looking at a new inhaled treatment for asthma that could help people with severe symptoms by targeting a specific receptor in the lungs, and it aims to find out if this treatment can reduce inflammation and make breathing easier.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Parmedics, INC. NIH-funded |
| Lab location | 1 site (Temecula, UNITED STATES) |
| Project ID | NIH-11051203 on NIH RePORTER |
What this research studies
This research focuses on developing a new aerosolized treatment for asthma that targets the protease-activated receptor-2 (PAR2). By understanding how PAR2 interacts with allergens and contributes to asthma symptoms, the study aims to create a more effective therapy for patients, particularly those with severe asthma. The approach involves using genetically modified animal models to explore the effects of the PAR2 antagonist, C781, on airway inflammation and hyper-responsiveness. If successful, this treatment could provide a new option for managing asthma exacerbations.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years who suffer from severe asthma and experience frequent exacerbations.
Not a fit: Patients with mild asthma or those who do not respond to inhaled corticosteroids may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment that significantly reduces asthma exacerbations and improves lung function in patients.
How similar studies have performed: While the approach of targeting PAR2 is innovative, similar studies have shown promise in understanding the role of receptor signaling in asthma treatment.
Where this research is happening
Temecula, UNITED STATES
- Parmedics, INC. — Temecula, United States (Active)
Researchers
- Principal investigator: Defea, Kathryn Anne — Parmedics, INC.
- Study coordinator: Defea, Kathryn Anne
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.